BioLineRx is currently focused on the development of BL-8040, which is a short peptide antagonist for CXCR4, a chemokine receptor involved with tumor progression, angiogenesis, metastasis and cell survival. BL-8040 is being developed for a variety of solid tumors including pancreatic, gastric and NSCLC. It is also being developed for AML and stem cell mobilization. They are also developing AGI-134, an alpha-gal immunotherapy for solid tumors, which is expected to enter the clinic within 12 months. BioLineRx has multiple collaborators including Genentech, Merck and Novartis.

Continue reading

This version is programmatically created by Research Central and qualified in its entirety to the original PDF.

Powered by Research Central